{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T03:39:42Z","timestamp":1777433982613,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European commission","doi-asserted-by":"publisher","award":["018698"],"award-info":[{"award-number":["018698"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.ygyno.2018.02.020","type":"journal-article","created":{"date-parts":[[2018,3,11]],"date-time":"2018-03-11T00:46:15Z","timestamp":1520729175000},"page":"371-380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patients\u2013 A study of the OVCAD consortium"],"prefix":"10.1016","volume":"149","author":[{"given":"Johanna M.","family":"Gostner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Obermayr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioana E.","family":"Braicu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Concin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Mahner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3984-2948","authenticated-orcid":false,"given":"Adriaan","family":"Vanderstichele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jalid","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignace","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietmar","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Zeillinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.ygyno.2018.02.020_bb0005","doi-asserted-by":"crossref","first-page":"6897","DOI":"10.1158\/1078-0432.CCR-04-0378","article-title":"Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases","volume":"10","author":"Allard","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2018.02.020_bb0010","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ctrv.2016.04.001","article-title":"The use of circulating tumor cells in guiding treatment decisions for patients with metastatic castration-resistant prostate cancer","volume":"46","author":"Onstenk","year":"2016","journal-title":"Cancer Treat. Rev."},{"issue":"3","key":"10.1016\/j.ygyno.2018.02.020_bb0015","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10147-017-1105-2","article-title":"Circulating tumor cells: clinical validity and utility","volume":"22","author":"Cabel","year":"2017","journal-title":"Int. J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2018.02.020_bb0020","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.cell.2016.11.037","article-title":"Emerging biological principles of metastasis","volume":"168","author":"Lambert","year":"2017","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.ygyno.2018.02.020_bb0025","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.7150\/jca.13098","article-title":"Circulating tumor cells (CTC) are associated with defects in adaptive immunity in patients with inflammatory breast cancer","volume":"7","author":"Mego","year":"2016","journal-title":"J. Cancer"},{"issue":"22","key":"10.1016\/j.ygyno.2018.02.020_bb0030","doi-asserted-by":"crossref","first-page":"35656","DOI":"10.18632\/oncotarget.10290","article-title":"Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer","volume":"8","author":"Mego","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.ygyno.2018.02.020_bb0035","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2174\/1389200024605082","article-title":"Neopterin as a marker for immune system activation","volume":"3","author":"Murr","year":"2002","journal-title":"Curr. Drug Metab."},{"issue":"3\u20134","key":"10.1016\/j.ygyno.2018.02.020_bb0040","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3109\/10408369209114604","article-title":"The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases","volume":"29","author":"Fuchs","year":"1992","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"issue":"1","key":"10.1016\/j.ygyno.2018.02.020_bb0045","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.canlet.2009.05.008","article-title":"Neopterin, a prognostic marker in human malignancies","volume":"287","author":"Sucher","year":"2010","journal-title":"Cancer Lett."},{"issue":"18","key":"10.1016\/j.ygyno.2018.02.020_bb0050","first-page":"4977","article-title":"Clinical significance of neopterin for prognosis and follow-up in ovarian cancer","volume":"47","author":"Reibnegger","year":"1987","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.ygyno.2018.02.020_bb0055","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1093\/annonc\/mdw248","article-title":"Long-term significance of urinary neopterin in ovarian cancer: a study by the Austrian Association for Gynecologic Oncology (AGO)","volume":"27","author":"Volgger","year":"2016","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2018.02.020_bb0060","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1525-1438.2006.00294.x","article-title":"Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies","volume":"16","author":"Melichar","year":"2006","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"9","key":"10.1016\/j.ygyno.2018.02.020_bb0065","first-page":"699","article-title":"Differential patterns of serum biomarkers of immune activation in human T-cell lymphotropic virus type I-associated myelopathy\/tropical spastic paraparesis, and adult T-cell leukemia\/lymphoma","volume":"5","author":"Giusti","year":"1996","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"5","key":"10.1016\/j.ygyno.2018.02.020_bb0070","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1517\/14728222.2014.995092","article-title":"The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment","volume":"19","author":"Gostner","year":"2015","journal-title":"Expert Opin. Ther. Targets"},{"issue":"3","key":"10.1016\/j.ygyno.2018.02.020_bb0075","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0165-2478(91)90005-U","article-title":"Increased endogenous interferon-gamma and neopterin correlate with increased degradation of tryptophan in human immunodeficiency virus type 1 infection","volume":"28","author":"Fuchs","year":"1991","journal-title":"Immunol. Lett."},{"issue":"10","key":"10.1016\/j.ygyno.2018.02.020_bb0080","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/nm934","article-title":"Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase","volume":"9","author":"Uyttenhove","year":"2003","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.ygyno.2018.02.020_bb0085","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1158\/1078-0432.CCR-05-1966","article-title":"Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells","volume":"12","author":"Brandacher","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ygyno.2018.02.020_bb0090","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.trim.2006.09.017","article-title":"Tryptophan catabolism generates autoimmune-preventive regulatory T cells","volume":"17","author":"Fallarino","year":"2006","journal-title":"Transpl. Immunol."},{"issue":"2","key":"10.1016\/j.ygyno.2018.02.020_bb0095","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/IGC.0b013e31827de6b9","article-title":"Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD","volume":"23","author":"Chekerov","year":"2013","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2018.02.020_bb0100","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2018.02.020_bb0105","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2012.09.021","article-title":"Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortium","volume":"128","author":"Obermayr","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2018.02.020_bb0110","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/clinchem\/40.2.265","article-title":"Commercial enzyme-linked immunosorbent assay for neopterin detection in blood donations compared with RIA and HPLC","volume":"40","author":"Mayersbach","year":"1994","journal-title":"Clin. Chem."},{"issue":"3","key":"10.1016\/j.ygyno.2018.02.020_bb0115","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/clinchem\/48.3.579","article-title":"More rapid method for simultaneous measurement of tryptophan and kynurenine by HPLC","volume":"48","author":"Laich","year":"2002","journal-title":"Clin. Chem."},{"issue":"1","key":"10.1016\/j.ygyno.2018.02.020_bb0120","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1515\/pterid-2014-0015","article-title":"Serum tryptophan, kynurenine, phenylalanine, tyrosine and neopterin concentrations in 100 healthy blood donors","volume":"26","author":"Geisler","year":"2015","journal-title":"Pteridines"},{"issue":"11","key":"10.1016\/j.ygyno.2018.02.020_bb0125","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nrc4019","article-title":"Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer","volume":"15","author":"Bowtell","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2018.02.020_bb0130","first-page":"950","article-title":"Neopterin as a prognostic indicator in patients with carcinoma of the uterine cervix","volume":"46","author":"Reibnegger","year":"1986","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.ygyno.2018.02.020_bb0135","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1073\/pnas.1113873109","article-title":"Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase","volume":"109","author":"Pilotte","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2018.02.020_bb0140","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/978-1-4615-0135-0_21","article-title":"T cell apoptosis by kynurenines","volume":"527","author":"Fallarino","year":"2003","journal-title":"Adv. Exp. Med. Biol."},{"issue":"2","key":"10.1016\/j.ygyno.2018.02.020_bb0145","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0165-2478(89)90120-X","article-title":"Endogenous release of interferon-gamma and diminished response of peripheral blood mononuclear cells to antigenic stimulation","volume":"23","author":"Fuchs","year":"1989","journal-title":"Immunol. Lett."},{"issue":"10","key":"10.1016\/j.ygyno.2018.02.020_bb0150","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nri1457","article-title":"IDO expression by dendritic cells: tolerance and tryptophan catabolism","volume":"4","author":"Mellor","year":"2004","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.ygyno.2018.02.020_bb0155","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1158\/1078-0432.CCR-16-1433","article-title":"Neoadjuvant chemotherapy of ovarian cancer results in three patterns of tumor-infiltrating lymphocyte response with distinct implications for immunotherapy","volume":"23","author":"Lo","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.ygyno.2018.02.020_bb0160","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/10408363.2014.896316","article-title":"Circulating tumor cells as promising novel biomarkers in solid cancers","volume":"51","author":"Lianidou","year":"2014","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"issue":"1","key":"10.1016\/j.ygyno.2018.02.020_bb0165","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2014.05.002","article-title":"Hematogenous metastasis of ovarian cancer: rethinking mode of spread","volume":"26","author":"Pradeep","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ygyno.2018.02.020_bb0170","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.trsl.2016.03.016","article-title":"New models of hematogenous ovarian cancer metastasis demonstrate preferential spread to the ovary and a requirement for the ovary for abdominal dissemination","volume":"175","author":"Coffman","year":"2016","journal-title":"Transl. Res."},{"issue":"16","key":"10.1016\/j.ygyno.2018.02.020_bb0175","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","article-title":"Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome","volume":"14","author":"Tothill","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ygyno.2018.02.020_bb0180","first-page":"113","article-title":"Indoleamine 2,3-dioxygenase promotes peritoneal dissemination of ovarian cancer through inhibition of natural killercell function and angiogenesis promotion","volume":"38","author":"Nonaka","year":"2011","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ygyno.2018.02.020_bb0185","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ebiom.2016.11.013","article-title":"IDO1 is an integral mediator of inflammatory neovascularization","volume":"14","author":"Mondal","year":"2016","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.ygyno.2018.02.020_bb0190","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological effects of conventional chemotherapy and targeted anticancer agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.ygyno.2018.02.020_bb0195","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nrc3144","article-title":"Rethinking ovarian cancer: recommendations for improving outcomes","volume":"11","author":"Vaughan","year":"2011","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2018.02.020_bb0200","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s00268-004-7812-7","article-title":"Roles of cyclophilins in cancers and other organ systems","volume":"29","author":"Yao","year":"2005","journal-title":"World J. Surg."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818301392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818301392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T05:39:37Z","timestamp":1603949977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825818301392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0090825818301392"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.02.020","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patients\u2013 A study of the OVCAD consortium","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}